These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 2779590

  • 21. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [Abstract] [Full Text] [Related]

  • 22. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF, Gao J, Durairajan SS, Man SC, Xie LX, Lu JH, Fong WL, Li M.
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [Abstract] [Full Text] [Related]

  • 23. The impact of treatment with levodopa on Parkinson's disease.
    Shaw KM, Lees AJ, Stern GM.
    Q J Med; 1980 Aug; 49(195):283-93. PubMed ID: 7465763
    [Abstract] [Full Text] [Related]

  • 24. [Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa].
    Svetel MV, Sternić NM, Filipović SR, Vojvodić NM, Kostić VS.
    Srp Arh Celok Lek; 1997 Aug; 125(7-8):203-6. PubMed ID: 9304232
    [Abstract] [Full Text] [Related]

  • 25. Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.
    Filipović SR, Rothwell JC, van de Warrenburg BP, Bhatia K.
    Mov Disord; 2009 Jan 30; 24(2):246-53. PubMed ID: 18951540
    [Abstract] [Full Text] [Related]

  • 26. Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade).
    Sharma JC, Macnamara L, Hasoon M, Vassallo M, Ross I.
    Parkinsonism Relat Disord; 2006 Dec 30; 12(8):499-505. PubMed ID: 16935018
    [Abstract] [Full Text] [Related]

  • 27. [Abnormal movements induced by L-dopa. New therapeutic possibilities].
    Eisenring J-J, Constantinidis J, Dick P, Yanniotis G, Tissot R.
    Schweiz Med Wochenschr; 1975 Jan 25; 105(4):121-4. PubMed ID: 1124379
    [Abstract] [Full Text] [Related]

  • 28. Sickness due to levodopa-induced neck dyskinesias in Parkinson's disease.
    Steiger MJ, Quinn NP, Marsden CD.
    Mov Disord; 1991 Jan 25; 6(1):91-2. PubMed ID: 2005934
    [No Abstract] [Full Text] [Related]

  • 29. [Cases of abnormal movements].
    Singer B.
    Sem Hop; 1991 Jan 25; 55(1-2):83-4. PubMed ID: 34219
    [Abstract] [Full Text] [Related]

  • 30. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.
    Carpentier AF, Bonnet AM, Vidailhet M, Agid Y.
    Neurology; 1996 Jun 25; 46(6):1548-51. PubMed ID: 8649546
    [Abstract] [Full Text] [Related]

  • 31. Psychiatric disturbances occurring during levodopa therapy of Parkinson's disease.
    Lloyd KG.
    Prim Care; 1977 Sep 25; 4(3):561-75. PubMed ID: 264230
    [Abstract] [Full Text] [Related]

  • 32. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.
    Marsden CD, Parkes JD.
    Lancet; 1976 Feb 07; 1(7954):292-6. PubMed ID: 55599
    [Abstract] [Full Text] [Related]

  • 33. Deanol in the treatment of levodopa-induced dyskinesias.
    Klawans HL, Topel JL, Bergen D.
    Neurology; 1975 Mar 07; 25(3):290-3. PubMed ID: 1167639
    [Abstract] [Full Text] [Related]

  • 34. Ventrolateral thalamotomy for dyskinesia following levodopa therapy of Parkinson's disease.
    Lee ST, Lu CS.
    J Formos Med Assoc; 1996 Dec 07; 95(12):943-5. PubMed ID: 9000814
    [Abstract] [Full Text] [Related]

  • 35. Treating and preventing levodopa-induced dyskinesias: current and future strategies.
    Durif F.
    Drugs Aging; 1999 May 07; 14(5):337-45. PubMed ID: 10408734
    [Abstract] [Full Text] [Related]

  • 36. Letter: Diphasic dyskinesia during levodopa therapy.
    Barbeau A.
    Lancet; 1975 Mar 29; 1(7909):756. PubMed ID: 47527
    [No Abstract] [Full Text] [Related]

  • 37. Risk factors for levodopa-induced dyskinesias in Parkinson's disease.
    Grandas F, Galiano ML, Tabernero C.
    J Neurol; 1999 Dec 29; 246(12):1127-33. PubMed ID: 10653303
    [Abstract] [Full Text] [Related]

  • 38. Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias.
    Tarsy D, Parkes JD, Marsden CD.
    J Neurol Neurosurg Psychiatry; 1975 Apr 29; 38(4):331-5. PubMed ID: 1095689
    [Abstract] [Full Text] [Related]

  • 39. [Therapeutic use of tiapride in movement disorders].
    Mathé JF, Cler JM, Venisse JL.
    Sem Hop; 1978 May 29; 54(13-16):517-20. PubMed ID: 211595
    [Abstract] [Full Text] [Related]

  • 40. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients.
    Blanchet PJ, Allard P, Grégoire L, Tardif F, Bédard PJ.
    Can J Neurol Sci; 1996 Aug 29; 23(3):189-93. PubMed ID: 8862840
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.